5 Drug Pricing Policy Developments To Watch In 2026

Manatt Health Partners and co-authored an article in Law360 analyzing the key pharmaceutical pricing issues that will shape federal and state policy in 2026.

The article reviews five policy areas expected to shape the drug‑pricing landscape this year, including CMS’ proposed most‑favored‑nation models, the launch of maximum fair prices under the Medicare Drug Price Negotiation Program, potential updates to the 340B program, evolving state efforts to regulate drug costs and new GLP‑1 pricing and coverage pathways. Dworkowitz and Kolber highlight how litigation, regulatory authority questions and varying levels of program participation may influence the impact and timing of these reforms.

“2026 promises to be a year of continued experimentation. Whether those efforts take hold ultimately may depend on whether courts conclude these efforts are consistent with both statutory and constitutional limitations,” wrote Dworkowitz and Kolber.

Law360 subscribers can read the full article .